Lay summary
Type 2 diabetes (T2D) affects ~300,000 New Zealanders, and a disproportionate number of Māori. This leads to significant disparity in health outcomes, including a 5x greater risk of cardiovascular and/or renal disease, longer hospital stays and increased mortality rates for Māori with T2D compared to non-Māori. We have partnered with Hauraki PHO, and propose to deliver and evaluate a new model of care comprised of wrap-around kaiāwhina support, optimised clinical support (with and without intermittent use of technology (continuous glucose monitors)) against ‘usual care’ in a cohort of mostly Māori T2D patients with sub-optimal glycaemic control. Based on a pilot study, we expect our model will significantly improve T2D management, glycaemic control and longer-term outcomes via the use of biofeedback and patient education, optimised medication titrations and use of new medications. Our model is primary care-led and we will determine the costs of translating this into ongoing practice.